A small double-blind, placebo-controlled study in China has shown there may be promise in the use of hydroxychloroquine in patients with COVID-19. The researchers randomized 62 people with early COVID-19 infection into two groups. The control group received placebo, and the treatment group received 200 mg of hydroxychloroquine (HCQ) twice daily for 5 days. Time to clinical recovery (TTCR), clinical characteristics, and radiological results were assessed at baseline and at the end of the study …
Read More![New Data Support Effectiveness of Hydroxychloroquine for COVID-19 New Data Support Effectiveness of Hydroxychloroquine for COVID-19](https://www.jucm.com/wp-content/uploads/2020/04/New-Data-Support-Effectiveness-image-380x253-1.jpg)